Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.66 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.66 |
| ▸ | GBA1 | P04062 | 1/20 | 0.63 |
| ▸ | ALDH1A1 | P00352 | 10/20 | 0.62 |
| ▸ | TSHR | P16473 | 1/20 | 0.61 |
| ▸ | LMNA | P02545 | 1/20 | 0.54 |
| ▸ | HPGD | P15428 | 1/20 | 0.54 |
| ▸ | HTT | P42858 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 2/20 | 0.51 |
| ▸ | CA9 | Q16790 | 2/20 | 0.51 |
| ▸ | CA2 | P00918 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6595288 | 0.85 | MEN1 (0.64) | MEN1KMT2AGBA1ALDH1A1TSHR | |
| SCHEMBL17255140 | 0.84 | KMT2A (0.63) | MEN1KMT2AGBA1ALDH1A1TSHR | |
| SCHEMBL30569570 | 0.83 | GBA1 (0.59) | MEN1KMT2AGBA1ALDH1A1TSHR | |
| SCHEMBL19392455 | 0.82 | MEN1 (0.61) | MEN1KMT2AALDH1A1LMNAHPGD | |
| SCHEMBL29960153 | 0.81 | MEN1 (0.59) | MEN1KMT2AALDH1A1LMNACA12 | |
| SCHEMBL21132292 | 0.81 | GBA1 (0.56) | MEN1KMT2AGBA1ALDH1A1TSHR | |
| SCHEMBL7862567 | 0.80 | GBA1 (0.74) | MEN1KMT2AGBA1ALDH1A1TSHR | |
| SCHEMBL29543465 | 0.79 | GBA1 (0.72) | MEN1KMT2AGBA1ALDH1A1TSHR | |
| SCHEMBL28686588 | 0.79 | GBA1 (0.67) | MEN1KMT2AGBA1ALDH1A1TSHR | |
| SCHEMBL17206014 | 0.79 | GBA1 (0.67) | MEN1KMT2AGBA1ALDH1A1TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-119954810-A | Regulator of fused ring derivative, preparation method and application thereof | 上海翰森生物医药科技有限公司 | 2025-05-09 | — | — | CN | disclosed |
| CN-112771025-B | Deuterated compounds as ROCK inhibitors | 重庆复创医药研究有限公司 | 2024-02-27 | — | — | CN | disclosed |
| WO-2023217230-A1 | KINESIN KIF18A INHIBITOR AND USE THEREOF | 上海湃隆生物科技有限公司 | 2023-11-16 | — | — | WO | disclosed |
| US-20230250080-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LTD (GB) | 2023-08-10 | — | — | US | disclosed |
| US-11613527-B2 | Enzyme inhibitors | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2023-03-28 | — | — | US | disclosed |
| EP-4010333-A1 | PLASMA KALLIKREIN INHIBITORS | Kalvista Pharmaceuticals Limited (GB) | 2022-06-15 | — | — | EP | disclosed |
| CN-114206852-A | Plasma kallikrein inhibitors | 卡尔维斯塔制药有限公司 | 2022-03-18 | — | — | CN | disclosed |
| US-20220048894-A1 | ENZYME INHIBITORS | KALVISTA PHARMACEUTICALS LIMITED (GB) | 2022-02-17 | — | — | US | disclosed |
| US-20070032537-A1 | 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases | ARENA PHARMACEUTICALS, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032537-A1 | 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases | ARENA PHARMACEUTICALS, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| US-20070032537-A1 | 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases | ARENA PHARMACEUTICALS, INC. (US) | 2007-02-08 | — | — | US | disclosed |
| EP-1633351-A1 | 5-SUBSTITUTED 2H-PYRAZOLE-3-CARBOXYLIC ACID DERIVATIVES AS AGONISTS FOR THE NICOTINIC ACID RECEPTOR RUP25 FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | Arena Pharmaceuticals, Inc. (US) | 2006-03-15 | — | — | EP | disclosed |
| WO-2005011677-A1 | 5-SUBSTITUTED 2H-PYRAZOLE-3-CARBOXYLIC ACID DERIVATIVES AS AGONISTS FOR THE NICOTINIC ACID RECEPTOR RUP25 FOR THE TREATMENT OF DYSLIPIDEMIA AND RELATED DISEASES | ARENA PHARMACEUTICALS, INC. (US) | 2005-02-10 | — | — | WO | disclosed |
| US-6825181-B1 | ORALLY ADMINISTRATED TO EXHIBIT A STRONG ANTICOAGULANT EFFECT BY INHIBITING ACTIVATED BLOOD- COAGULATION FACTOR X | AJINOMOTO CO., INC. (JP) | 2004-11-30 | — | — | US | disclosed |
| EP-1065200-A1 | AMINOISOQUINOLINE DERIVATIVES | Ajinomoto Co., Inc. (JP) | 2001-01-03 | — | — | EP | disclosed |
| EP-0757061-B1 | Sulfonamido substituted acetal polymers and use thereof in photosensitive compositions and lithographic printing plates | KODAK POLYCHROME GRAPHICS LLC (US) | 2000-09-13 | — | — | EP | disclosed |
| US-5849842-A | Sulfonamido substituted acetal polymers | KODAK POLYCHROME GRAPHICS, LLC (US) | 1998-12-15 | — | — | US | disclosed |
| US-5698360-A | Sulfonamido substituted acetal polymers and use thereof in photo-sensitive compositions and lithographic printing plates | SUN CHEMICAL CORPORATION (US) | 1997-12-16 | — | — | US | disclosed |
| EP-0757061-A2 | Sulfonamido substituted acetal polymers and use thereof in photosensitive compositions and lithographic printing plates | SUN CHEMICAL CORPORATION (US) | 1997-02-05 | — | — | EP | disclosed |
| US-3969358-A | Process for the preparation of thieno [3,2-c] pyridine and thieno [2,3-c] py | PARCOR (FR) | 1976-07-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230250080-A1 | ENZYME INHIBITORS | SERPINB1, KLKB1, SERPINE1 | MEN1 602/4885KMT2A 1556/4885GBA1 237/4885 |
| US-11613527-B2 | Enzyme inhibitors | SERPINB1, KLKB1, SERPINE1 | MEN1 602/4885KMT2A 1556/4885GBA1 237/4885 |
| US-20070032537-A1 | 5-Substituted 2h-pyrazole-3-carboxylic acid derivatives as agonists for the acid receptor rup25 for the treatment of dyslipidemia and related diseases | ACE, AGTR2, ACE2 | MEN1 4781/4885KMT2A 3934/4885GBA1 537/4885 |
| US-20220048894-A1 | ENZYME INHIBITORS | SERPINB1, KLKB1, SERPINE1 | MEN1 602/4885KMT2A 1556/4885GBA1 237/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.